替雷利珠单抗及化疗联合放疗治疗晚期非小细胞肺癌患者的临床观察
Clinical Observation of Tislelizumab and Chemotherapy Combined with Radiotherapy in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer
摘要: 目的：探讨替雷利珠单抗及化疗联合放疗治疗晚期驱动基因阴性的非小细胞肺癌(Non-Small Cell Lung Cancer, NSCLC)的临床疗效及不良反应。方法：回顾性分析2021年3月~2024年10月在湘西自治州人民医院采用免疫化疗联合放疗的11例晚期NSCLC患者，观察其疗效及不良反应。结果：其中位无进展生存期(Polymeric Ferric Sulfate, PFS)为11.10月；不良反应发生情况：6例发生过III~IV级不良反应，其中3例为IV级为骨髓抑制，已纠正。结论：替雷利珠单抗联合化疗及放疗治疗晚期驱动基因阴性非小细胞肺癌显示出令人鼓舞的疗效和可管理的不良反应。
Abstract: Objective: To explore the clinical efficacy and adverse reactions of tislelizumab and chemotherapy combined with radiotherapy in the treatment of advanced driver gene-negative Non-Small Cell Lung Cancer (NSCLC). Methods: A retrospective analysis was conducted on 11 patients with advanced NSCLC who received immunochemotherapy combined with radiotherapy in the People’s Hospital of Xiangxi Autonomous Prefecture from March 2021 to October 2024. The therapeutic effect and adverse reactions were observed. Result: The median progression-free survival (Polymeric Ferric Sulfate, PFS) was 11.10 months; adverse reaction occurrence: Grade III~IV adverse reactions occurred in 6 cases, among which 3 cases were grade IV bone marrow suppression, which has been corrected. Conclusion: Tislelizumab combined with chemotherapy and radiotherapy has shown encouraging efficacy and manageable adverse reactions in the treatment of advanced driver gene-negative non-small cell lung cancer.
文章引用：罗尘, 隆涛, 赵景胜. 替雷利珠单抗及化疗联合放疗治疗晚期非小细胞肺癌患者的临床观察[J]. 临床医学进展, 2025, 15(10): 469-474. https://doi.org/10.12677/acm.2025.15102779

参考文献

[1] 秦娜, 马红霞, 靳光付, 等. 肺癌流行病学研究年度进展2022 [J]. 中华医学杂志, 2023, 103(14): 1068-1073.
[2] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., et al. (2021) Five-Year Outcomes with Pembrolizumab versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, 39, 2339-2349. [Google Scholar] [CrossRef] [PubMed]
[3] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375, 1823-1833. [Google Scholar] [CrossRef] [PubMed]
[4] 陈大卫, 尚士洁, 于金明. 重新认识放射治疗在肿瘤综合治疗中的作用[J]. 中国科学基金, 2025, 39(1): 34-49.
[5] 中华医学会肿瘤学分会. 中华医学会肺癌临床诊疗指南(2024版) [J]. 中华医学杂志, 2024, 104(34): 3175-3213.
[6] 王宁, 王宝华. 全球肺癌负担、防治现况与展望[J]. 结核与肺部疾病杂志, 2025, 6(3): 256-260.
[7] 叶晟劼, 吴智明, 王包晟, 等. 非小细胞肺癌病例术后呼吸道感染病原微生物分布及耐药性分析[J]. 中国病原生物学杂志, 2025, 20(5): 638-641.
[8] Stading, R., Gastelum, G., Chu, C., Jiang, W. and Moorthy, B. (2021) Molecular Mechanisms of Pulmonary Carcinogenesis by Polycyclic Aromatic Hydrocarbons (PAHs): Implications for Human Lung Cancer. Seminars in Cancer Biology, 76, 3-16. [Google Scholar] [CrossRef] [PubMed]
[9] 林小峰, 陈龙. 晚期非小细胞肺癌化疗现状及进展[J]. 广西医科大学学报, 2019, 36(5): 850-855.
[10] Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., et al. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378, 2078-2092. [Google Scholar] [CrossRef] [PubMed]
[11] Garassino, M.C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., et al. (2023) Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study. Journal of Clinical Oncology, 41, 1992-1998. [Google Scholar] [CrossRef] [PubMed]
[12] Novello, S., Kowalski, D.M., Luft, A., Gümüş, M., Vicente, D., Mazières, J., et al. (2023) Pembrolizumab plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of Clinical Oncology, 41, 1999-2006. [Google Scholar] [CrossRef] [PubMed]
[13] Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., et al. (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 379, 2040-2051. [Google Scholar] [CrossRef] [PubMed]
[14] 游琪. 免疫疗法对肺癌的“秘密武器”还是“空中楼阁”? [J]健康必读, 2025(17): 45-46.
[15] 宋溢, 祁玮, 刘亚利. 营养风险筛查2002与预后营养指数对老年局部晚期肺癌鳞状细胞癌放疗患者预后的影响[J]. 中国临床医生杂志, 2024, 52(6): 670-673
[16] Narayan, R.S., Fedrigo, C.A., Brands, E., Dik, R., Stalpers, L.J.A., Baumert, B.G., et al. (2017) The Allosteric AKT Inhibitor MK2206 Shows a Synergistic Interaction with Chemotherapy and Radiotherapy in Glioblastoma Spheroid Cultures. BMC Cancer, 17, Article No. 204. [Google Scholar] [CrossRef] [PubMed]
[17] 刘明博. 放疗化疗联合应用诱导肺癌细胞死亡及其机制研究[D]: [硕士学位论文]. 长春: 吉林大学, 2011.
[18] Hennequin, C., Guillerm, S. and Quero, L. (2019) Combination of Chemotherapy and Radiotherapy: A Thirty Years Evolution. Cancer/Radiothérapie, 23, 662-665. [Google Scholar] [CrossRef] [PubMed]
[19] Goff, P.H., Zeng, J., Rengan, R. and Schaub, S.K. (2021) Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung Cancer. Seminars in Radiation Oncology, 31, 133-139. [Google Scholar] [CrossRef] [PubMed]
[20] Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R.R., et al. (2014) Irradiation and Anti-PD-L1 Treatment Synergistically Promote Antitumor Immunity in Mice. Journal of Clinical Investigation, 124, 687-695. [Google Scholar] [CrossRef] [PubMed]
[21] Sato, H., Niimi, A., Yasuhara, T., Permata, T.B.M., Hagiwara, Y., Isono, M., et al. (2017) DNA Double-Strand Break Repair Pathway Regulates PD-L1 Expression in Cancer Cells. Nature Communications, 8, Article No. 1751. [Google Scholar] [CrossRef] [PubMed]
[22] Ding, P., Huang, Y., Tong, F., Chen, L., Wen, L., Zhang, R., et al. (2022) MA09.04 First-Line PD-1 Inhibitors and Chemotherapy Combined with or without Radiotherapy in Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 17, S75. [Google Scholar] [CrossRef] 

为你推荐